New York biopharmaceutical firm inks research deal with Washington University

The New York-based public company is tapping Washington University to lead efforts to advance a drug candidate targeting Alzheimer's disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.